FDA Clears Abaloparatide for High-Risk Osteoporosis Patients
Abaloparatide is the first new anabolic treatment approved for postmenopausal women with osteoporosis in the United States in nearly 15 years. FDA Approvals …read more
Abaloparatide is the first new anabolic treatment approved for postmenopausal women with osteoporosis in the United States in nearly 15 years. FDA Approvals …read more
The latest maternal mortality numbers and strategies to improve care will be discussed at the upcoming American Congress of Obstetricians and Gynecologists (ACOG) meeting. Medscape Medical News …read more
New research suggests that the majority of women with symptoms of urinary tract infection probably are infected, despite negative result on standard test. …read more
Women who have migraine headaches, particularly migraine without aura, are at increased risk for hypertension, a new study suggests. Medscape Medical News …read more
Mortality rates for women undergoing surgery for abdominal aortic aneurysms are nearly twice those for men, a new study has found. …read more
Scientists in the United States have developed a fluid-filled womb-like bag known as an extra-uterine support device that could transform care for extremely premature babies, significantly improving chances of survival. Reuters Health Information …read more
These management strategies can help enhance the care of women with adnexal masses. Medscape Ob/Gyn …read more
A new EMAS position paper on the appropriate use of a drug holiday following treatment for osteoporosis in patients at low risk for fracture concurs with that of the American Society for Bone and Mineral Research. Medscape Medical News …read more
Medscape Medical News …read more
A lack of understanding among clinicians about genetic information is contributing toward unnecessary bilateral mastectomies. Medscape Medical News …read more